Advertisement

Tislelizumab Plus Chemotherapy for Recurrent/Metastatic Nasopharyngeal Cancer: RATIONALE-309
Posted: 05/04/2022 | By: Sarah Campen, PharmD

Question 1 of 5

At a median follow-up of 15.5 months, the median time to disease progression or death after next-line therapy for patients treated with tislelizumab plus chemotherapy vs chemotherapy alone, respectively, was:

Choose 1

A
Not reached vs 15.2 months (hazard ratio [HR] = 0.89)
B
13.9 months vs 9.6 months (HR = 0.50)
C
15.2 months vs 7.4 months (HR = 0.43)
D
Not reached vs 13.9 months (HR = 0.38)

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage